SKB profits up as drug sales dive
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.THIRD-quarter results from SmithKline Beecham, the Anglo- American drugs and healthcare group, yesterday provided evidence of the way healthcare reforms are to affect pharmaceutical profits, writes Gail Counsell.
Although pre-tax profits were up in line with expectations, growth in drug sales was significantly below the same period last year.
Drug sales rose only 2 per cent, generating trading profits up 8 per cent. In comparison the same quarter last year saw pharmaceutical sales up 24 per cent.
Some of the difference was accounted for by abnormally high 1992 sales of its hepatitis B vaccine, Engerix B. But the company also stressed that profit growth was coming entirely from volume and not price increases, while regional figures demonstrated the relative slackness of the key US market.
Group third-quarter pre-tax profits rose 9 per cent at pounds 291m on sales 20 per cent higher at pounds 1.5bn, giving earnings per share of 7.5p, up from 6.7p. Nine-month profits were up 13 per cent at pounds 892m on sales up 25 per cent at pounds 4.4bn, pushing earnings up from 19.3p a share to 22.2p.
The dividend per 'A' share is 2.533p (2.075p). The results were in line with expectations and the shares rose 9p to 414p.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments